Page last updated: 2024-11-01

nomifensine and Movement Disorders

nomifensine has been researched along with Movement Disorders in 4 studies

Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.

Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.

Research Excerpts

ExcerptRelevanceReference
"These mice provide a valid model of Parkinson's disease and are a resource for the investigation of pathogenesis and therapeutics."1.35Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. ( Beal, MF; Bogdanov, M; Burke, RE; Geghman, K; Jackson-Lewis, V; Li, C; Li, Y; Liu, W; Oo, TF; Przedborski, S; Tang, Y; Wang, L; Zhou, C, 2009)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19902 (50.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, Y1
Liu, W1
Oo, TF1
Wang, L1
Tang, Y1
Jackson-Lewis, V1
Zhou, C1
Geghman, K1
Bogdanov, M1
Przedborski, S1
Beal, MF1
Burke, RE1
Li, C1
Campbell, JM1
Gilmore, DP1
Russell, D1
Growney, CA1
Favor, G1
Kennedy, AK1
Davies, RW1
Payne, AP1
Stone, TW1
Schultz, W1
Scarnati, E1
Sundström, E1
Romo, R1
Mihatsch, W1
Russ, H1
Przuntek, H1

Other Studies

4 other studies available for nomifensine and Movement Disorders

ArticleYear
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
    Nature neuroscience, 2009, Volume: 12, Issue:7

    Topics: Age Factors; Animals; Antiparkinson Agents; Apomorphine; Brain; Chromosomes, Artificial, Bacterial;

2009
Pharmacological analysis of extracellular dopamine and metabolites in the striatum of conscious as/agu rats, mutants with locomotor disorder.
    Neuroscience, 2000, Volume: 100, Issue:1

    Topics: Amphetamine; Animals; Clorgyline; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Uptake Inhibi

2000
Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by the catecholamine uptake inhibitor nomifensine: behavioral analysis in monkeys with partial striatal dopamine depletions.
    Neuroscience, 1989, Volume: 31, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Female; Macaca fascicularis;

1989
Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine.
    Journal of neural transmission, 1988, Volume: 71, Issue:3

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain; Catecholamines; Caudate Nucleus; Dose-Response Relation

1988
chemdatabank.com